Skip to main content
Oncoinvent ASA logo

Oncoinvent ASA — Investor Relations & Filings

Ticker · OCIN ISIN · NO0010779341 LEI · 54930076H5GUZRMSNR39 Euronext Growth Manufacturing
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-11-14 Share Issue/Capital Cha…
Country NO Norway
Listing Euronext Growth OCIN

About Oncoinvent ASA

https://www.oncoinvent.com/

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies for cancer. The company's core focus is on direct alpha therapy, a technology platform designed to deliver potent, short-range radiation directly to cancerous tumors. Its lead product candidate, Radspherin®, is composed of inorganic microparticles that carry the alpha-emitting radionuclide Radium-224. This formulation is engineered for regional retention and slow degradation, enabling a high radiation dose to be administered within the peritoneal cavity while minimizing systemic exposure. Oncoinvent's clinical programs are primarily investigating the use of Radspherin® for treating metastatic cancers in the peritoneal cavity, including ovarian and colorectal cancer.

Recent filings

Filing Released Lang Actions
Oncoinvent ASA - Receipt of subscription rights in the rights issue by primary insiders and their close associates
Share Issue/Capital Change Classification · 100% confidence The document is a notification regarding the receipt of subscription rights by primary insiders in a rights issue. This falls under the category of reporting transactions or dealings by company insiders (primary insiders) in relation to company securities. While it mentions a rights issue, the core subject is the disclosure of insider activity as required by the EU Market Abuse Regulation, which aligns with the 'Director's Dealing' category.
2025-11-14 English
Oncoinvent ASA: EX. SUBSCRIPTION RIGHTS IN RIGHTS ISSUE TODAY
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement regarding an 'ex-date' for a rights issue. It does not contain the full financial report or the prospectus itself, but rather serves as a formal notification of a capital change event. Based on the 'Menu vs Meal' rule and the nature of the content, it is classified as a share issue/capital change announcement.
2025-11-12 English
Oncoinvent ASA: Terms of the underwritten Rights Issue
Capital/Financing Update Classification · 100% confidence The document is an announcement from Oncoinvent ASA regarding the terms of an underwritten rights issue, including the subscription price, share capital reduction, and the number of new shares to be issued. This falls under capital structure changes and financing activities. While it mentions a prospectus, the document itself is an announcement of the terms of the rights issue, which is a classic 'Capital/Financing Update'.
2025-11-11 English
Oncoinvent ASA: Updated Key Information related to the contemplated Rights Issue
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement from Oncoinvent ASA regarding the 'Key Information' for a contemplated Rights Issue. It details specific financial parameters such as the subscription price, record date, ex-date, and the number of new shares. This falls under the category of capital structure changes and financing activities. While it mentions a prospectus, the document itself is an announcement of the terms of the rights issue, not the prospectus itself, and it is not a report publication announcement (RPA) because it provides the substantive financial details of the offering rather than just notifying of a report's availability.
2025-11-11 English
Reminder: Invitation to presentation of Q3 2025 company update on November 4[th], 2025
Report Publication Announcement Classification · 100% confidence The document is a short invitation (3163 characters) to a Q3 2025 company update presentation. It does not contain the actual financial results or the full report, but rather serves as an announcement of an upcoming event where information will be shared. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-11-03 English
NOTIFICATION OF MAJOR HOLDINGS - Attachment: Notification of major holding Linc AB 2025-11-03 sent to Oslo Boers.pdf
Major Shareholding Notification Classification · 100% confidence The document is a 'Standard form for notification of major holdings' which explicitly details a change in share ownership (Linc AB acquiring 7.68% of Oncoinvent AS). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ), which tracks when entities cross specific ownership thresholds.
2025-11-03 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.